Sysmex’s Alzheimer’s Disease Blood Assay Kits Approved in Japan

Japan-headquartered Sysmex has received approval in Japan for two assay kits to measure blood amyloid beta, an indicator for Alzheimer’s disease.

Testing for Alzheimer’s currently includes sampling cerebral spinal fluid or advanced imaging tests such as positron emission tomography. The newly approved HISCL β-Amyloid 1-42 assay and HISCL β-Amyloid 1-40 assay kits offer an inexpensive alternative.

Sysmex inked a collaboration deal with Eisai in February 2016 to develop new diagnostic reagents for dementia, including for Alzheimer’s. Sysmex said it plans to launch the new blood test “as soon as possible.”